CLIS:TASEClal Insurance Enterprises Holdings Limited Analysis
Data as of 2026-06-12 - not real-time
ILA 25,790.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Clal Insurance trades at roughly 7.6% of its discounted cash‑flow estimate, with a market price of 25,790 versus a DCF fair value of 338,603, suggesting a deep discount. The stock’s PE ratio of 9.3 is well below the industry average of 16.6, while the price‑to‑book of 1.9 and dividend yield of 1.95% indicate attractive value and sustainable income given a modest payout ratio of 9%. Fundamentals remain solid: revenue grew 6.6% YoY, operating margin sits near 27%, and free cash flow of over 16.4 billion underscores strong liquidity.
Technical signals are mixed: the price sits below the 20‑day (26,925) and 50‑day (26,197) SMAs, the RSI at 44 signals neutral momentum, and a bearish MACD histogram (-285) points to short‑term downside pressure, though the broader trend is still classified as bullish. Volume is increasing, supporting the potential for a bounce toward the identified resistance around 29,440.
Risk considerations include a relatively low beta of 0.25 and a 30‑day volatility of nearly 39%, indicating price swings but limited market‑wide correlation. The company’s strong cash position, low debt‑to‑equity concerns (despite a high absolute debt figure), and limited regulatory and currency exposure make the downside risk manageable, aligning with a medium‑term upside thesis.
Technical signals are mixed: the price sits below the 20‑day (26,925) and 50‑day (26,197) SMAs, the RSI at 44 signals neutral momentum, and a bearish MACD histogram (-285) points to short‑term downside pressure, though the broader trend is still classified as bullish. Volume is increasing, supporting the potential for a bounce toward the identified resistance around 29,440.
Risk considerations include a relatively low beta of 0.25 and a 30‑day volatility of nearly 39%, indicating price swings but limited market‑wide correlation. The company’s strong cash position, low debt‑to‑equity concerns (despite a high absolute debt figure), and limited regulatory and currency exposure make the downside risk manageable, aligning with a medium‑term upside thesis.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram indicating short‑term downside
- Price below 20‑day and 50‑day SMAs
- RSI near neutral territory
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation gap between market price and DCF fair value
- Strong free cash flow and low payout ratio supporting dividend sustainability
- Increasing volume suggesting accumulation
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Robust ROE (~23%) and stable operating margins
- Low beta and defensive insurance sector profile
- Attractive yield and ample liquidity for future growth
Key Metrics & Analysis
Financial Health
Revenue Growth6.60%
Profit Margin13.30%
P/E Ratio9.3
ROE22.88%
ROA2.19%
Debt/Equity166.43
P/B Ratio1.9
Op. Cash FlowILA1.1B
Free Cash FlowILA16.5B
Industry P/E16.6
Technical Analysis
TrendBullish
RSI44.0
SupportILA 24,450.00
ResistanceILA 29,440.00
MA 20ILA 26,925.00
MA 50ILA 26,197.20
MA 200ILA 21,767.35
MACDBearish
VolumeIncreasing
Fear & Greed Index87.79
Valuation
Fair ValueILA 338,603.45
Target PriceILA 29,000.00
Upside/Downside12.45%
GradeUndervalued
TypeBlend
Dividend Yield1.95%
Risk Assessment
Beta0.25
Volatility38.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.